• Publications
  • Influence
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
TLDR
It is demonstrated that pocket profiles are nearly independent of the remaining HLA-DR cleft, and this approach has implications for the development of epitope-based vaccines.
Human neoplasms elicit multiple specific immune responses in the autologous host.
TLDR
The unexpected frequency of human tumor antigens indicates that human neoplasms elicit multiple specific immune responses in the autologous host and provides diagnostic and therapeutic approaches to human cancer.
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
TLDR
R reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma, which indicates that it belongs to an expanding family of immunogenic testicular antigens.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
mRNA-based therapeutics — developing a new class of drugs
TLDR
This Review provides a comprehensive overview of the current state of mRNA-based drug technologies and their applications, and discusses the key challenges and opportunities in developing these into a new class of drugs.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
TLDR
The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
TLDR
It is shown that DCs can be targeted precisely and effectively in vivo using intravenously administered RNA-lipoplexes (RNA-LPX) based on well-known lipid carriers by optimally adjusting net charge, without the need for functionalization of particles with molecular ligands.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
TLDR
The first-in-human application of individualized mutanome vaccines in melanoma is reported, demonstrating that individual mutations can be exploited and opening a path to personalized immunotherapy for patients with cancer.
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
TLDR
Investigation of SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1-1.7 lineage spike protein finds that the immune sera of 16 participants in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to both variants.
...
1
2
3
4
5
...